Asaoku Y, Jyo T, Mochiduki N, Kodomari Y, Kuwabara M, Yoshizane T, Shigeta S, Ono K, Tsuboi S, Ootsuka T
Third Department of Internal Medicine, Hiroshima Prefectual Hiroshima Hospital.
Arerugi. 1995 Jul;44(7):692-700.
At present, we are performing desensitization immunotherapy on patients with mite-positive bronchial asthma using purified mite feces antigen fractions. We obtained the following results in 13 patients 4 to 12 months after the start of treatment. 1) The fraction showing the maximum reaction in the skin test was HM1-2 (molecular weight: 150-155 kD) in two patients, HM2 (30-40 kD) in nine patients and HM3 (10-20 kD) in two patients, and immunotherapy was performed using these fractions. None of the patients showed the maximum skin reactions or was treated with HM4 (less than 10 kD). 2) In nine patients with perennial asthma, the effects of treatment were excellent in four and moderate in three, while two cases remained unchanged. In four patients with seasonal asthma, the treatment was effective in all cases. 3) In patients in whom immunotherapy was effective, specific IgG antibody increased after the treatment, but it did not increase in the unchanged cases. Among the subclasses of specific IgG antibody increased by the treatment, no clear changes were seen in IgG4 antibody and no conclusion has been reached at present. 4) None of the patients had definite adverse reactions such as the occurrence of asthma attacks or anaphylaxis. These results suggested that purified mite feces antigens are safe and effective. We plan to continue this study with more patients in the future.
目前，我们正在使用纯化的螨粪抗原组分对螨阳性支气管哮喘患者进行脱敏免疫治疗。在治疗开始4至12个月后，我们对13例患者获得了以下结果。1）皮肤试验中显示最大反应的组分，2例患者为HM1-2（分子量：150-155 kD），9例患者为HM2（30-40 kD），2例患者为HM3（10-20 kD），并使用这些组分进行免疫治疗。没有患者出现最大皮肤反应或接受HM4（小于10 kD）治疗。2）在9例常年性哮喘患者中，4例治疗效果极佳，3例中等，2例无变化。在4例季节性哮喘患者中，治疗在所有病例中均有效。3）在免疫治疗有效的患者中，治疗后特异性IgG抗体增加，但在无变化的病例中未增加。在治疗后增加的特异性IgG抗体亚类中，IgG4抗体未见明显变化，目前尚未得出结论。4）没有患者出现哮喘发作或过敏反应等明确的不良反应。这些结果表明，纯化的螨粪抗原是安全有效的。我们计划未来对更多患者继续这项研究。
